MetaVia (NASDAQ:MTVA) Cut to “Sell” at Wall Street Zen

MetaVia (NASDAQ:MTVA) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. HC Wainwright raised their target price on MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $36.50.

MetaVia Stock Up 3.0%

Shares of MTVA stock opened at $2.43 on Friday. The stock has a 50-day moving average price of $7.12 and a 200 day moving average price of $8.35. MetaVia has a 12 month low of $2.32 and a 12 month high of $23.10. The firm has a market cap of $5.35 million, a price-to-earnings ratio of -0.29 and a beta of 0.27.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.86) by $1.32. Sell-side analysts predict that MetaVia will post -3.9 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MetaVia

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC increased its holdings in MetaVia Inc. (NASDAQ:MTVA) by 44.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the period. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 at the end of the most recent quarter. 1.37% of the stock is currently owned by institutional investors and hedge funds.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.